47 results on '"Finnes, Heidi D"'
Search Results
2. High-Dose Methotrexate in Patients With Lymphoma: Predictors of a Complicated Course
3. Selinexor (Xpovio™)
4. Efficacy of Second-Line Chemotherapy in Extrapulmonary Neuroendocrine Carcinoma
5. Talazoparib (Talzenna™)
6. Binimetinib (Mektovi®)
7. High-Dose Methotrexate in Patients With Lymphoma: Predictors of a Complicated Course
8. Hematology‐oncology pharmacists: We hear you, we see you, we support you
9. Adapting investigational drug services during a pandemic: Recommendations for future preparedness from the Hematology/Oncology Pharmacy Association Investigational Drug Services Special Interest Group
10. Encorafenib (Braftovi™)
11. Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience
12. Durvalumab (Imfinzi™)
13. Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management
14. Adapting investigational drug services during a pandemic: Recommendations for future preparedness from the Hematology/Oncology Pharmacy Association Investigational Drug Services Special Interest Group.
15. National Comprehensive Cancer Network investigational drug service consensus recommendations
16. Successful encorafenib desensitization in a patient with recurrent metastatic melanoma
17. Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice
18. The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice
19. Intratumoral CD3+ and CD8+ T-Cell Densities in Patients With DNA Mismatch Repair–Deficient Metastatic Colorectal Cancer Receiving Programmed Cell Death-1 Blockade
20. Rheumatic Syndromes Associated With Immune Checkpoint Inhibitors: A Single‐Center Cohort of Sixty‐One Patients
21. 2019-2020 Drug Updates in Hematologic Malignancies.
22. Clinical outcome of patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) treated with pembrolizumab.
23. Safety and tolerability of the bolus 5-fluorouracil (5-FU) based FLOX and IFL regimens in patients who developed fluoropyrimidine-induced coronary vasospasm during therapy with infusional 5-FU or capecitabine.
24. Acalabrutinib (Calquence®)
25. Molecular Modeling and Functional Analysis of Exome Sequencing–Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma
26. Venetoclax (Venclexta™)
27. Response to pembrolizumab in patients with mismatch repair deficient (dMMR) colorectal cancer (CRC).
28. Response to pembrolizumab in patients with mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).
29. Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma
30. Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer
31. Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice
32. Efficacy, safety, and dose adjustment of cyclophosphamide in lymphoma patients requiring hemodialysis
33. Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma.
34. The Importance of Pharmacovigilance during Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice
35. Ipilimumab-induced colitis in patients with metastatic melanoma
36. Impact of Ibrutinib and Idelalisib on the Pharmaceutical Cost of Treating Chronic Lymphocytic Leukemia at the Individual and Societal Levels
37. Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.
38. Efficacy, safety, and dose adjustment of cyclophosphamide in lymphoma patients requiring hemodialysis.
39. Mo1273 Ipilimumab-Induced Colitis in Patients With Metastatic Melanoma
40. Sa1312 Systemic Corticosteroids Required Only for Moderate-to-Severe Ipilimumab-Induced Hepatitis
41. Drug–drug interaction between bosutinib and warfarin
42. Multiple Myeloma: Updates in Management.
43. CYP3A inhibitors and adverse outcomes in patients treated with docetaxel chemotherapy.
44. Comparison of toxicity, efficacy, and dose modifications in obese and non-obese patients receiving modified FOLFOX6 (mFOLFOX) for metastatic colorectal cancer (mCRC).
45. National Comprehensive Cancer Network investigational drug service consensus recommendations.
46. 2019-2020 Drug Updates in Hematologic Malignancies.
47. Intratumoral CD3 + and CD8 + T-Cell Densities in Patients With DNA Mismatch Repair-Deficient Metastatic Colorectal Cancer Receiving Programmed Cell Death-1 Blockade.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.